Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Earnings analysis
Organogenesis Holdings Inc. · ORGO · Third quarter 2026

Organogenesis Q3: revenue falls 70% as cost cuts fail to keep pace, and cash drops to $26.9M

Wound care sales fell 73% year on year and the company is now in a loss-making, cash-burning phase, while 2026 revenue guidance was narrowed toward a slower Q4 recovery.

15 Nov 2026 · CompePharma editorial
$45.5 million (vs $150.5 million in Q3 2025)Q3 2026 net revenue
$38.2 million, a decrease of 73%Advanced Wound Care revenue
52% of net product revenue (vs 76%)Q3 gross margin
$29.6 million, or $(0.25) per shareQ3 net loss
loss of $22.4 million (vs income of $30.1 million)Q3 Adjusted EBITDA
$26.9 million, no outstanding debt obligationsCash, cash equivalents and restricted cash

The quarter in numbers

Organogenesis reported third-quarter 2026 net revenue of $45.5 million, down $105.0 million, or 70%, from $150.5 million a year earlier. Advanced Wound Care (AWC) accounted for $38.2 million, down 73%. Surgical & Sports Medicine contributed $7.3 million, down 19%.

The bottom line swung from profit to loss. The company reported a net loss of $29.6 million, or $(0.25) per share, against net income of $21.6 million, or $0.11 per share, in Q3 2025. Adjusted net loss was $29.3 million versus adjusted net income of $23.2 million. Adjusted EBITDA was a loss of $22.4 million versus income of $30.1 million, a $52.5 million deterioration. The operating loss was $29.5 million versus operating income of $20.7 million.

The nine-month picture is starker. Net product revenue was $124.5 million, down 63% from $338.0 million. The net loss was $179.1 million, or $(1.47) per share, versus a loss of $6.7 million, or $(0.12), a year earlier.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.

More CP+ Earnings analysisAll →
CP+ Earnings analysis
CorMedix Inc. · CRMD · Third quarter 2026

CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook

$54.5 millionQ3 2026 consolidated revenue$17.2 millionDefenCath net revenue$14.7 millionQ3 2026 net loss

Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.

17 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Iambic Therapeutics, Inc. · IAM · Third quarter 2026

Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn

$11.4 million (vs $4.7 million in Q3 2025)Q3 2026 collaboration revenue$34.1 million (vs $23.1 million)Q3 2026 R&D expenses$38.5 million (vs $21.5 million)Q3 2026 net loss

Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.

16 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Alumis Inc. · ALMS · Third quarter 2026

Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path

$1.9 million (vs $2.1 million in Q3 2025)Q3 2026 collaboration revenue$80.8 million (vs $97.8 million)Q3 2026 R&D expenses$94.9 million (vs $110.8 million)Q3 2026 net loss

Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.

16 Nov 2026 · CompePharma editorial